BioTalent has published its latest report, Pharma and biotech 2030: Building the execution engine for the next decade of biopharma, offering a strategic perspective on how the industry’s competitive dynamics are evolving.
As new modalities, digital infrastructure and operational complexity reshape the sector, the ability to translate innovation and investment into reliable execution is becoming the defining factor in long-term performance. This report brings together BioTalent’s Talent Science insights with market analysis supported by L.E.K. Consulting to examine how organisations can build the capabilities required to succeed through 2030.
Drawing on industry data and workforce performance modelling, the report explores the structural forces transforming biopharma – from the rise of complex modalities such as ADCs, radiopharmaceuticals and CGT, to the increasing importance of digitally integrated manufacturing environments. It highlights how workforce capability, digital maturity and scientific platforms must operate as a unified execution system if companies are to convert capital and innovation into consistent operational and financial outcomes.
Dive into the full report to discover the trends shaping the next decade of biopharma and what they mean for leadership teams building future-ready organisations.
BioTalent would like to thank L.E.K. Consulting for their valuable support and contribution to this report.